tiprankstipranks
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
US Market
SNDX
Syndax Pharmaceuticals
RESEARCH TOOLSreports
Want to see SNDX full AI Analyst Report?

Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

950 Followers
See the Price Targets and Ratings of:

SNDX Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Syndax
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SNDX Stock 12 Month Forecast

Average Price Target

$38.67
▲(85.81% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $38.67 with a high forecast of $57.00 and a low forecast of $29.00. The average price target represents a 85.81% change from the last price of $20.81.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","58":"$58","19.75":"$19.75","32.5":"$32.5","45.25":"$45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,19.75,32.5,45.25,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.89,23.66769230769231,26.445384615384615,29.223076923076924,32.00076923076923,34.77846153846154,37.55615384615385,40.33384615384615,43.11153846153846,45.88923076923077,48.66692307692308,51.44461538461539,54.222307692307695,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.89,22.257435897435897,23.624871794871794,24.99230769230769,26.359743589743587,27.727179487179484,29.094615384615384,30.46205128205128,31.829487179487177,33.19692307692307,34.56435897435897,35.93179487179487,37.29923076923077,{"y":38.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.89,21.513846153846153,22.13769230769231,22.76153846153846,23.385384615384616,24.00923076923077,24.633076923076924,25.256923076923076,25.880769230769232,26.504615384615384,27.12846153846154,27.752307692307692,28.376153846153848,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.35,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.14,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.11,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$57.00Average Price Target$38.67Lowest Price Target$29.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on SNDX
Jason Zemansky
Bank of America Securities
Bank of America Securities
$29
Buy
39.36%
Upside
Reiterated
07/22/26
Bank of America Securities Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)
Barclays Analyst forecast on SNDX
Etzer Darout
Barclays
Barclays
$37
Buy
77.80%
Upside
Assigned
07/20/26
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst
H.C. Wainwright Analyst forecast on SNDX
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
92.22%
Upside
Reiterated
07/15/26
Syndax: Expanding High-Potential Pipeline and Disciplined Strategy Support Unchanged $40 Price Target and Buy Rating
TD Cowen Analyst forecast on SNDX
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/15/26
Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Syndax Pharmaceuticals (SNDX)
Stifel Nicolaus Analyst forecast on SNDX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$46
Buy
121.05%
Upside
Reiterated
07/15/26
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and HCA Healthcare (NYSE: HCA)
Citi Analyst forecast on SNDX
Yigal Nochomovitz
Citi
Citi
$57
Buy
173.91%
Upside
Reiterated
07/14/26
Syndax: Advancing Menin Inhibitor and Fibrosis/Oncology Pipeline Supports High-Risk, High-Reward Buy Rating
Guggenheim Analyst forecast on SNDX
Bradley Canino
Guggenheim
Guggenheim
$31
Buy
48.97%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Goldman Sachs Analyst forecast on SNDX
Corinne Johnson
Goldman Sachs
Goldman Sachs
$34
Buy
63.38%
Upside
Reiterated
07/14/26
Syndax: Strengthening Pipeline and R&D Outlook Support Buy Rating and Unchanged $34 Price Target
UBS Analyst forecast on SNDX
David Dai
UBS
UBS
$38→$37
Buy
77.80%
Upside
Reiterated
05/13/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from UBS
Jefferies Analyst forecast on SNDX
Faisal Khurshid
Jefferies
Jefferies
$40→$37
Buy
77.80%
Upside
Reiterated
05/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (NYSE: CNC) and Syndax Pharmaceuticals (NASDAQ: SNDX)
Mizuho Securities Analyst forecast on SNDX
Salim Syed
Mizuho Securities
Mizuho Securities
$45→$43
Buy
106.63%
Upside
Reiterated
03/30/26
Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
J.P. Morgan Analyst forecast on SNDX
Anupam Rama
J.P. Morgan
J.P. Morgan
$33→$45
Buy
116.24%
Upside
Reiterated
03/09/26
Syndax price target raised to $45 from $33 at JPMorganSyndax price target raised to $45 from $33 at JPMorgan
BTIG Analyst forecast on SNDX
Justin Zelin
BTIG
BTIG
$56
Buy
169.10%
Upside
Reiterated
01/02/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG
B. Riley Securities Analyst forecast on SNDX
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$33
Buy
58.58%
Upside
Reiterated
10/03/25
Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities
Scotiabank Analyst forecast on SNDX
George Farmer
Scotiabank
Scotiabank
$17
Hold
-18.31%
Downside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on SNDX
Jason Zemansky
Bank of America Securities
Bank of America Securities
$29
Buy
39.36%
Upside
Reiterated
07/22/26
Bank of America Securities Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)
Barclays Analyst forecast on SNDX
Etzer Darout
Barclays
Barclays
$37
Buy
77.80%
Upside
Assigned
07/20/26
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst
H.C. Wainwright Analyst forecast on SNDX
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
92.22%
Upside
Reiterated
07/15/26
Syndax: Expanding High-Potential Pipeline and Disciplined Strategy Support Unchanged $40 Price Target and Buy Rating
TD Cowen Analyst forecast on SNDX
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/15/26
Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Syndax Pharmaceuticals (SNDX)
Stifel Nicolaus Analyst forecast on SNDX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$46
Buy
121.05%
Upside
Reiterated
07/15/26
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and HCA Healthcare (NYSE: HCA)
Citi Analyst forecast on SNDX
Yigal Nochomovitz
Citi
Citi
$57
Buy
173.91%
Upside
Reiterated
07/14/26
Syndax: Advancing Menin Inhibitor and Fibrosis/Oncology Pipeline Supports High-Risk, High-Reward Buy Rating
Guggenheim Analyst forecast on SNDX
Bradley Canino
Guggenheim
Guggenheim
$31
Buy
48.97%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Goldman Sachs Analyst forecast on SNDX
Corinne Johnson
Goldman Sachs
Goldman Sachs
$34
Buy
63.38%
Upside
Reiterated
07/14/26
Syndax: Strengthening Pipeline and R&D Outlook Support Buy Rating and Unchanged $34 Price Target
UBS Analyst forecast on SNDX
David Dai
UBS
UBS
$38→$37
Buy
77.80%
Upside
Reiterated
05/13/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from UBS
Jefferies Analyst forecast on SNDX
Faisal Khurshid
Jefferies
Jefferies
$40→$37
Buy
77.80%
Upside
Reiterated
05/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (NYSE: CNC) and Syndax Pharmaceuticals (NASDAQ: SNDX)
Mizuho Securities Analyst forecast on SNDX
Salim Syed
Mizuho Securities
Mizuho Securities
$45→$43
Buy
106.63%
Upside
Reiterated
03/30/26
Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
J.P. Morgan Analyst forecast on SNDX
Anupam Rama
J.P. Morgan
J.P. Morgan
$33→$45
Buy
116.24%
Upside
Reiterated
03/09/26
Syndax price target raised to $45 from $33 at JPMorganSyndax price target raised to $45 from $33 at JPMorgan
BTIG Analyst forecast on SNDX
Justin Zelin
BTIG
BTIG
$56
Buy
169.10%
Upside
Reiterated
01/02/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG
B. Riley Securities Analyst forecast on SNDX
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$33
Buy
58.58%
Upside
Reiterated
10/03/25
Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities
Scotiabank Analyst forecast on SNDX
George Farmer
Scotiabank
Scotiabank
$17
Hold
-18.31%
Downside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Syndax Pharmaceuticals

3 Months
Justin ZelinBTIG
Success Rate
10/19 ratings generated profit
53%
Average Return
+6.64%
Copying Justin Zelin's trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +6.64% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
11/20 ratings generated profit
55%
Average Return
+6.83%
Copying Anupam Rama's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +6.83% per trade.
2 Years
Jason ZemanskyBank of America Securities
Success Rate
13/24 ratings generated profit
54%
Average Return
+15.69%
Copying Jason Zemansky's trades and holding each position for 2 Years would result in 54.17% of your transactions generating a profit, with an average return of +15.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SNDX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
11
9
12
14
18
Buy
5
6
4
4
6
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
15
16
18
24
In the current month, SNDX has received 24 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SNDX average Analyst price target in the past 3 months is 38.67.
Each month's total comprises the sum of three months' worth of ratings.

SNDX Financial Forecast

SNDX Earnings Forecast

Next quarter’s earnings estimate for SNDX is -$0.45 with a range of -$0.67 to -$0.33. The previous quarter’s EPS was -$0.48. SNDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.90% of the time in the same period. In the last calendar year SNDX has Performed in-line its overall industry.
Next quarter’s earnings estimate for SNDX is -$0.45 with a range of -$0.67 to -$0.33. The previous quarter’s EPS was -$0.48. SNDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.90% of the time in the same period. In the last calendar year SNDX has Performed in-line its overall industry.

SNDX Sales Forecast

Next quarter’s sales forecast for SNDX is $79.36M with a range of $72.00M to $88.43M. The previous quarter’s sales results were $64.86M. SNDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.39% of the time in the same period. In the last calendar year SNDX has Performed in-line its overall industry.
Next quarter’s sales forecast for SNDX is $79.36M with a range of $72.00M to $88.43M. The previous quarter’s sales results were $64.86M. SNDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.39% of the time in the same period. In the last calendar year SNDX has Performed in-line its overall industry.

SNDX Stock Forecast FAQ

What is SNDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Syndax Pharmaceuticals Inc’s 12-month average price target is 38.67.
    What is SNDX’s upside potential, based on the analysts’ average price target?
    Syndax Pharmaceuticals Inc has 85.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SNDX a Buy, Sell or Hold?
          Syndax Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Syndax Pharmaceuticals Inc’s price target?
            The average price target for Syndax Pharmaceuticals Inc is 38.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $57.00 ,the lowest forecast is $29.00. The average price target represents 85.81% Increase from the current price of $20.81.
              What do analysts say about Syndax Pharmaceuticals Inc?
              Syndax Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of SNDX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.